Sign up to save your podcasts
Or
Share S14 Ep19: Zidesamtinib Is Associated With CNS Activity and Low Rates of Neurologic AEs in Pretreated ROS1+ NSCLC: With Alexander Drilon, MD
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
S14 Ep19: Zidesamtinib Is Associated With CNS Activity and Low Rates of Neurologic AEs in Pretreated ROS1+ NSCLC: With Alexander Drilon, MD
In today’s episode, we had the pleasure of speaking with Alexander Drilon, MD, about the phase 1/2 ARROS-1 trial (NCT05118789) investigating zidesamtinib (NVL-520) in TKI-pretreated patients with advanced ROS1-positive non–small cell lung cancer (NSCLC). Dr Drilon is chief of the Early Drug Development Service at Memorial Sloan Kettering Cancer Center in New York, New York.
In our exclusive interview, Dr Drilon discussed the efficacy data and implications of the ARROS-1 trial, highlighted the unique mechanism of action of zidesamtinib, noted the high central nervous system (CNS) response rates and favorable safety profile associated with the agent, and emphasized the potential for zidesamtinib to become a standard first-line therapy in the NSCLC treatment paradigm, especially for patients with prior TKI resistance or CNS disease.
View all episodes
By OncLive® On Air
4.3
2222 ratings
In today’s episode, we had the pleasure of speaking with Alexander Drilon, MD, about the phase 1/2 ARROS-1 trial (NCT05118789) investigating zidesamtinib (NVL-520) in TKI-pretreated patients with advanced ROS1-positive non–small cell lung cancer (NSCLC). Dr Drilon is chief of the Early Drug Development Service at Memorial Sloan Kettering Cancer Center in New York, New York.
In our exclusive interview, Dr Drilon discussed the efficacy data and implications of the ARROS-1 trial, highlighted the unique mechanism of action of zidesamtinib, noted the high central nervous system (CNS) response rates and favorable safety profile associated with the agent, and emphasized the potential for zidesamtinib to become a standard first-line therapy in the NSCLC treatment paradigm, especially for patients with prior TKI resistance or CNS disease.
More shows like OncLive® On Air
View all
JAMA Editors' Summary
135 Listeners
NEJM This Week
321 Listeners
JAMA Clinical Reviews
496 Listeners
Research To Practice | Oncology Videos
115 Listeners
ASCO Daily News
57 Listeners
Core IM | Internal Medicine Podcast
1,154 Listeners
The ONS Podcast
197 Listeners
OncoPharm
187 Listeners
JAMA Medical News
90 Listeners
The Clinical Problem Solvers
515 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
364 Listeners
Oncology Today with Dr Neil Love
58 Listeners
CCO Oncology Podcast
9 Listeners
Two Onc Docs
189 Listeners
Oncology Brothers: Practice-Changing Cancer Discussions
42 Listeners